CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: CTSS (ImmuneEditome ID:1520)

1. Gene summary of enriched editing regions for CTSS

check button Gene summary
Gene informationGene symbol

CTSS

Gene ID

1520

GeneSynonyms-
GeneCytomap

1q21.3

GeneTypeprotein-coding
GeneDescriptioncathepsin S
GeneModificationdate20230403
UniprotIDA0A7P0TB77;P25774;A0A7P0T8U1;A0A7P0T904;U3KQE7;A0A804DAZ0;A0A7P0T8H4;A0A7P0T844;A0A7P0TAQ0;A0A7P0T8A1;A0A7P0T7Z6
PubMed ID

35732347

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:150731082-150734568:-ENST00000368985.6ENSG00000163131.9CTSSexonicAluJo,AluSx,AluSz6,AluJr4,AluSz,MamRep434,AluSpchr1:150731082-150734568:-.alignment
chr1:150731082-150734568:-ENST00000448301.5ENSG00000163131.9CTSSexonicAluJo,AluSx,AluSz6,AluJr4,AluSz,MamRep434,AluSpchr1:150731082-150734568:-.alignment
chr1:150731082-150734568:-ENST00000472977.5ENSG00000163131.9CTSSexonicAluJo,AluSx,AluSz6,AluJr4,AluSz,MamRep434,AluSpchr1:150731082-150734568:-.alignment
chr1:150731082-150734568:-ENST00000607427.1ENSG00000163131.9CTSSexonicAluJo,AluSx,AluSz6,AluJr4,AluSz,MamRep434,AluSpchr1:150731082-150734568:-.alignment
chr1:150740453-150742182:-ENST00000368985.6ENSG00000163131.9CTSSintronicAluJo,AluSc,AluJr4,AluY,AluSx1,L1ME4achr1:150740453-150742182:-.alignment
chr1:150740453-150742182:-ENST00000448301.5ENSG00000163131.9CTSSintronicAluJo,AluSc,AluJr4,AluY,AluSx1,L1ME4achr1:150740453-150742182:-.alignment
chr1:150740453-150742182:-ENST00000472977.5ENSG00000163131.9CTSSintronicAluJo,AluSc,AluJr4,AluY,AluSx1,L1ME4achr1:150740453-150742182:-.alignment
chr1:150740453-150742182:-ENST00000483930.1ENSG00000163131.9CTSSintronicAluJo,AluSc,AluJr4,AluY,AluSx1,L1ME4achr1:150740453-150742182:-.alignment
chr1:150753026-150754260:-ENST00000480760.1ENSG00000163131.9CTSSncRNA_intronic(AAACA)n,AluSx1,AluJb,MER2chr1:150753026-150754260:-.alignment


Top

2. Tumor-specific enriched editing regions for CTSS


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:150731082-150734568:-BRCAEER4.9967e-06image
ENSG00000163131.9,CTSSBRCAEAG7.7679e-06image
chr1:150731082-150734568:-COADEER7.2102e-05image
ENSG00000163131.9,CTSSCOADEAG9.1500e-05image
chr1:150731082-150734568:-KIRPEER3.7233e-04image
ENSG00000163131.9,CTSSKIRPEAG4.2409e-04image
chr1:150731082-150734568:-LUADEER2.8314e-02image
ENSG00000163131.9,CTSSLUADEAG3.0045e-02image
chr1:150731082-150734568:-LUSCEER1.6370e-02image
ENSG00000163131.9,CTSSLUSCEAG1.8421e-02image
chr1:150731082-150734568:-STADEER1.8594e-02image
ENSG00000163131.9,CTSSSTADEAG1.6177e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000163131.9,CTSSKIRCPathEAG4.6508e-031.7297e-020.1054image
chr1:150731082-150734568:-KIRCPathEER3.3816e-031.5589e-020.1070image
chr1:150731082-150734568:-STADPathEER4.9146e-024.5752e-020.1069image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr1:150731082-150734568:-COADEER4.5947e-024.5081e-032.5885e+03image
ENSG00000163131.9,CTSSCOADEAG4.5947e-025.1885e-032.3484e+03image
chr1:150731082-150734568:-READEER1.4890e-021.1953e-025.4080e+06image
ENSG00000163131.9,CTSSREADEAG1.4890e-021.2072e-025.0451e+06image

Top

3. Enriched editing regions and immune related genes for CTSS


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:150731082-150734568:-PAADEERENSG00000091129,NRCAM-0.39622.3421e-041.2069e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NRCAMNK_cells_activatedGSVA_HALLMARK_P53_PATHWAY
chr1:150731082-150734568:-PAADEERENSG00000165661,QSOX2-0.38052.7521e-041.6594e-09-0.4404imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAEosinophilsGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000156298,TSPAN7-0.38553.5280e-044.4880e-08-0.4034imageNTAF15;ADAR;ELAVL1;KHSRP;NOP56NAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000183741,CBX6-0.37263.8215e-048.8848e-09-0.4221imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAMacrophages_M0GSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000100580,TMED8-0.37825.1153e-043.2087e-08-0.4074imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NANK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000100604,CHGA-0.37755.7803e-043.1054e-08-0.4077imageNTAF15;ADAR;ELAVL1;NOP56CHGAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000109339,MAPK10-0.35828.2927e-041.2068e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56MAPK10NK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000082397,EPB41L3-0.35968.9696e-043.1478e-08-0.4076imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NAMacrophages_M0GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000170088,TMEM192-0.36181.0792e-034.5407e-08-0.4032imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000171291,ZNF439-0.34961.4848e-033.0322e-08-0.4080imageNTAF15;ELAVL1NAT_cells_CD4_naiveGSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000091129,NRCAM-0.39622.3421e-041.2069e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NRCAMNK_cells_activatedGSVA_HALLMARK_P53_PATHWAY
chr1:150731082-150734568:-PAADEERENSG00000165661,QSOX2-0.38052.7521e-041.6594e-09-0.4404imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAEosinophilsGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000156298,TSPAN7-0.38553.5280e-044.4880e-08-0.4034imageNTAF15;ADAR;ELAVL1;KHSRP;NOP56NAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000183741,CBX6-0.37263.8215e-048.8848e-09-0.4221imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAMacrophages_M0GSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000100580,TMED8-0.37825.1153e-043.2087e-08-0.4074imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NANK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000100604,CHGA-0.37755.7803e-043.1054e-08-0.4077imageNTAF15;ADAR;ELAVL1;NOP56CHGAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000109339,MAPK10-0.35828.2927e-041.2068e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56MAPK10NK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000082397,EPB41L3-0.35968.9696e-043.1478e-08-0.4076imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NAMacrophages_M0GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000170088,TMEM192-0.36181.0792e-034.5407e-08-0.4032imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000171291,ZNF439-0.34961.4848e-033.0322e-08-0.4080imageNTAF15;ELAVL1NAT_cells_CD4_naiveGSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000091129,NRCAM-0.39622.3421e-041.2069e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NRCAMNK_cells_activatedGSVA_HALLMARK_P53_PATHWAY
chr1:150731082-150734568:-PAADEERENSG00000165661,QSOX2-0.38052.7521e-041.6594e-09-0.4404imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAEosinophilsGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000156298,TSPAN7-0.38553.5280e-044.4880e-08-0.4034imageNTAF15;ADAR;ELAVL1;KHSRP;NOP56NAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000183741,CBX6-0.37263.8215e-048.8848e-09-0.4221imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAMacrophages_M0GSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000100580,TMED8-0.37825.1153e-043.2087e-08-0.4074imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NANK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000100604,CHGA-0.37755.7803e-043.1054e-08-0.4077imageNTAF15;ADAR;ELAVL1;NOP56CHGAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000109339,MAPK10-0.35828.2927e-041.2068e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56MAPK10NK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000082397,EPB41L3-0.35968.9696e-043.1478e-08-0.4076imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NAMacrophages_M0GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000170088,TMEM192-0.36181.0792e-034.5407e-08-0.4032imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000171291,ZNF439-0.34961.4848e-033.0322e-08-0.4080imageNTAF15;ELAVL1NAT_cells_CD4_naiveGSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000091129,NRCAM-0.39622.3421e-041.2069e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NRCAMNK_cells_activatedGSVA_HALLMARK_P53_PATHWAY
chr1:150731082-150734568:-PAADEERENSG00000165661,QSOX2-0.38052.7521e-041.6594e-09-0.4404imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAEosinophilsGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000156298,TSPAN7-0.38553.5280e-044.4880e-08-0.4034imageNTAF15;ADAR;ELAVL1;KHSRP;NOP56NAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000183741,CBX6-0.37263.8215e-048.8848e-09-0.4221imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAMacrophages_M0GSVA_HALLMARK_GLYCOLYSIS
chr1:150731082-150734568:-PAADEERENSG00000100580,TMED8-0.37825.1153e-043.2087e-08-0.4074imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NANK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000100604,CHGA-0.37755.7803e-043.1054e-08-0.4077imageNTAF15;ADAR;ELAVL1;NOP56CHGAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000109339,MAPK10-0.35828.2927e-041.2068e-08-0.4187imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56MAPK10NK_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-PAADEERENSG00000082397,EPB41L3-0.35968.9696e-043.1478e-08-0.4076imageNKHDRBS1;TAF15;ADAR;ELAVL1;NOP56NAMacrophages_M0GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000170088,TMEM192-0.36181.0792e-034.5407e-08-0.4032imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-PAADEERENSG00000171291,ZNF439-0.34961.4848e-033.0322e-08-0.4080imageNTAF15;ELAVL1NAT_cells_CD4_naiveGSVA_HALLMARK_GLYCOLYSIS

More results



Top

4. Enriched editing regions and immune related splicing for CTSS


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000163131.9,CTSS
LIHCEAGESENSG00000166925.4chr7100474273:100474440:100477276:100478307:100478793:100479169-0.14272.9735e-021.2334e-14-0.4378imageNADAR;CPSF6;CSTF2T;DDX3X;DHX9;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;MBNL2;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
ENSG00000163131.9,CTSS
PAADEAGA3ENSG00000196535.10chr1729118044:29118189:29116443:29116455:29116443:29117710-0.33181.7947e-021.5535e-08-0.4251imageNADAR;CPSF6;CSTF2T;DDX3X;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;MBNL2;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM27;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;WTAP;YTHDC1MYO18AT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000163131.9,CTSS
PAADEAGESENSG00000136628.13chr1220010945:220011056:220018125:220018146:220018448:220018508-0.24884.2100e-023.5436e-08-0.4130imageNADAR;CPSF6;CSTF2T;DDX3X;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28B;MBNL2;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM27;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TNRC6A;TROVE2;U2AF2;UPF1;YTHDC1NAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
chr1:150731082-150734568:-
PAADEERA3ENSG00000166313.14chr116402081:6402209:6401051:6401688:6401051:64019820.39671.1676e-033.0067e-090.4412imageNTAF15;ADAR;ELAVL1;NOP56APBB1NK_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-
PAADEERESENSG00000166313.14chr116401586:6401688:6401976:6401982:6402081:6402209-0.39581.1711e-033.7759e-09-0.4387imageNTAF15;ADAR;ELAVL1;NOP56APBB1NK_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000163131.9,CTSS
PAADEAGA3ENSG00000166313.14chr116402081:6402209:6401051:6401688:6401051:64019820.39341.1033e-033.2774e-090.4402imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;MBNL2;NOP56;NOP58;PRPF8;PTBP1;RBM10;SRSF1;SRSF3;TAF15;U2AF2;UPF1APBB1NK_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-
PAADEERIRENSG00000095066.7chr1912765689:12765724:12765828:127658340.28054.3117e-025.3575e-070.4244imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56HOOK2NK_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr1:150731082-150734568:-
PAADEERESENSG00000136628.13chr1220010945:220011056:220018125:220018146:220018448:220018508-0.24724.4128e-023.9913e-08-0.4115imageNKHDRBS1;TAF15;ADAR;ELAVL1;KHSRP;NOP56NAMast_cells_activatedGSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000163131.9,CTSS
PAADEAGESENSG00000166313.14chr116401586:6401688:6401976:6401982:6402081:6402209-0.39231.1964e-034.1236e-09-0.4377imageNADAR;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;MBNL2;NOP56;NOP58;PRPF8;PTBP1;RBM10;SRSF1;SRSF3;TAF15;U2AF2;UPF1APBB1NK_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000163131.9,CTSS
PAADEAGIRENSG00000095066.7chr1912765689:12765724:12765828:127658340.27894.6745e-025.2425e-070.4248imageNADAR;CPSF6;CSTF2T;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;HNRNPA1;HNRNPA2B1;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBM10;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;U2AF2;UPF1HOOK2NK_cells_activatedGSVA_HALLMARK_PANCREAS_BETA_CELLS

More results



Top

5. Enriched editing regions and immune infiltration for CTSS


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:150731082-150734568:-ACCEERMast_cells_activated2.8480e-020.3011image
ENSG00000163131.9,CTSSACCEAGMast_cells_activated4.2364e-020.2799image
chr1:150731082-150734568:-BLCAEERNeutrophils1.6830e-020.1319image
ENSG00000163131.9,CTSSBLCAEAGNeutrophils1.3690e-020.1354image
chr1:150731082-150734568:-BRCAEERT_cells_CD4_naive5.0204e-03-0.0875image
ENSG00000163131.9,CTSSBRCAEAGT_cells_CD4_naive5.0964e-03-0.0874image
chr1:150731082-150734568:-CESCEERDendritic_cells_activated5.7933e-030.1713image
ENSG00000163131.9,CTSSCESCEAGDendritic_cells_activated1.0556e-020.1587image
chr1:150731082-150734568:-COADEERMast_cells_activated1.4597e-020.1469image
ENSG00000163131.9,CTSSCOADEAGMast_cells_activated1.1331e-020.1522image
chr1:150731082-150734568:-ESCAEERB_cells_naive1.7219e-020.1881image
ENSG00000163131.9,CTSSESCAEAGB_cells_naive1.5856e-020.1904image
chr1:150731082-150734568:-GBMEERNK_cells_resting4.7703e-03-0.2180image
ENSG00000163131.9,CTSSGBMEAGNK_cells_resting5.2306e-03-0.2158image
chr1:150731082-150734568:-HNSCEERMacrophages_M13.1184e-040.1726image
ENSG00000163131.9,CTSSHNSCEAGMacrophages_M14.2513e-040.1688image
chr1:150731082-150734568:-KICHEERMacrophages_M12.3515e-050.5505image
ENSG00000163131.9,CTSSKICHEAGMacrophages_M12.4939e-050.5491image
chr1:150731082-150734568:-KIRCEERT_cells_regulatory_(Tregs)2.3722e-040.1900image
ENSG00000163131.9,CTSSKIRCEAGT_cells_regulatory_(Tregs)4.2137e-040.1824image
chr1:150731082-150734568:-KIRPEERMacrophages_M08.7933e-030.1660image
ENSG00000163131.9,CTSSKIRPEAGMacrophages_M08.1948e-030.1676image
chr1:150731082-150734568:-LAMLEERT_cells_follicular_helper3.2090e-040.2918image
chr1:150753026-150754260:-LAMLEERB_cells_naive4.2737e-020.3662image
ENSG00000163131.9,CTSSLAMLEAGT_cells_follicular_helper3.0168e-040.2930image
chr1:150731082-150734568:-LGGEERT_cells_CD4_naive6.0486e-03-0.1328image
ENSG00000163131.9,CTSSLGGEAGT_cells_CD4_naive6.1369e-03-0.1326image
chr1:150731082-150734568:-LIHCEERDendritic_cells_resting2.3470e-020.1276image
ENSG00000163131.9,CTSSLIHCEAGMast_cells_resting2.5333e-02-0.1256image
chr1:150731082-150734568:-LUADEERT_cells_CD4_memory_resting1.0014e-02-0.1138image
ENSG00000163131.9,CTSSLUADEAGT_cells_CD4_memory_resting1.2613e-02-0.1103image
chr1:150731082-150734568:-OVEERB_cells_memory9.9640e-03-0.1552image
ENSG00000163131.9,CTSSOVEAGB_cells_memory6.1496e-03-0.1642image
chr1:150731082-150734568:-PAADEERB_cells_naive4.1536e-03-0.2181image
ENSG00000163131.9,CTSSPAADEAGB_cells_naive5.0232e-03-0.2136image
chr1:150731082-150734568:-PCPGEERT_cells_CD4_memory_activated4.6299e-030.2824image
ENSG00000163131.9,CTSSPCPGEAGT_cells_CD4_memory_activated7.8252e-040.3306image
chr1:150731082-150734568:-PRADEERB_cells_naive1.2374e-030.1653image
ENSG00000163131.9,CTSSPRADEAGB_cells_naive1.2433e-030.1652image
chr1:150731082-150734568:-READEERNeutrophils4.7124e-02-0.2053image
ENSG00000163131.9,CTSSREADEAGNeutrophils4.3669e-02-0.2086image
chr1:150731082-150734568:-SARCEERT_cells_gamma_delta5.8459e-030.1828image
ENSG00000163131.9,CTSSSARCEAGT_cells_gamma_delta5.8902e-030.1822image
chr1:150731082-150734568:-SKCMEERT_cells_CD81.4400e-030.1558image
ENSG00000163131.9,CTSSSKCMEAGT_cells_CD82.5534e-030.1475image
chr1:150731082-150734568:-STADEERMacrophages_M11.5461e-020.1256image
chr1:150740453-150742182:-STADEERT_cells_follicular_helper2.8889e-02-0.4556image
ENSG00000163131.9,CTSSSTADEAGMacrophages_M12.1425e-020.1194image
chr1:150731082-150734568:-TGCTEERT_cells_CD4_naive1.0608e-03-0.2872image
ENSG00000163131.9,CTSSTGCTEAGT_cells_CD4_naive1.0581e-03-0.2873image
chr1:150731082-150734568:-THCAEERT_cells_gamma_delta3.1060e-02-0.0982image
ENSG00000163131.9,CTSSTHCAEAGT_cells_gamma_delta3.6604e-02-0.0952image
chr1:150731082-150734568:-THYMEERMast_cells_resting4.9647e-030.2969image
ENSG00000163131.9,CTSSTHYMEAGMast_cells_resting4.7231e-030.2986image
chr1:150731082-150734568:-UCECEERMacrophages_M13.0022e-020.1950image
ENSG00000163131.9,CTSSUCECEAGT_cells_gamma_delta2.9616e-020.1939image
chr1:150731082-150734568:-UVMEERNK_cells_activated3.5201e-020.3340image
ENSG00000163131.9,CTSSUVMEAGNK_cells_activated3.5977e-020.3326image


Top

6. Enriched editing regions and immune gene sets for CTSS


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:150731082-150734568:-ACCGSVA_HALLMARK_APICAL_SURFACEEER1.7409e-030.4200image
ENSG00000163131.9,CTSSACCGSVA_HALLMARK_APICAL_SURFACEEAG1.8650e-030.4176image
chr1:150731082-150734568:-BLCAGSVA_HALLMARK_ANGIOGENESISEER7.3007e-030.1479image
ENSG00000163131.9,CTSSBLCAGSVA_HALLMARK_ANGIOGENESISEAG8.4160e-030.1446image
chr1:150731082-150734568:-BRCAGSVA_HALLMARK_DNA_REPAIREER3.7186e-060.1439image
ENSG00000163131.9,CTSSBRCAGSVA_HALLMARK_DNA_REPAIREAG4.8087e-060.1422image
ENSG00000163131.9,CTSSCESCGSVA_HALLMARK_APICAL_SURFACEEAG4.2857e-03-0.1769image
chr1:150731082-150734568:-CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3239e-03-0.1888image
ENSG00000163131.9,CTSSCHOLGSVA_HALLMARK_GLYCOLYSISEAG3.6434e-020.3713image
chr1:150731082-150734568:-CHOLGSVA_HALLMARK_GLYCOLYSISEER3.6791e-020.3706image
ENSG00000163131.9,CTSSCOADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG8.5978e-03-0.1579image
chr1:150731082-150734568:-COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.8804e-03-0.1572image
ENSG00000163131.9,CTSSESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6893e-030.2463image
chr1:150731082-150734568:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5186e-030.2487image
ENSG00000163131.9,CTSSGBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5269e-030.2441image
chr1:150731082-150734568:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4726e-030.2449image
ENSG00000163131.9,CTSSHNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.9999e-070.2337image
chr1:150731082-150734568:-HNSCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.6642e-070.2396image
ENSG00000163131.9,CTSSKICHGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.9103e-040.4471image
chr1:150731082-150734568:-KICHGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.7147e-040.4478image
ENSG00000163131.9,CTSSKIRCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4506e-09-0.3079image
chr1:150731082-150734568:-KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEER6.6442e-10-0.3139image
ENSG00000163131.9,CTSSKIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.5065e-030.2005image
chr1:150731082-150734568:-KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.8592e-030.1967image
ENSG00000163131.9,CTSSLAMLGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.6382e-02-0.1722image
chr1:150753026-150754260:-LAMLGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.0680e-02-0.3887image
chr1:150731082-150734568:-LAMLGSVA_HALLMARK_MITOTIC_SPINDLEEER2.4959e-02-0.1843image
chr1:150731082-150734568:-LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.2986e-050.1997image
ENSG00000163131.9,CTSSLGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.5033e-050.1991image
ENSG00000163131.9,CTSSLIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG7.5402e-040.1883image
chr1:150731082-150734568:-LIHCGSVA_HALLMARK_UV_RESPONSE_DNEER1.4113e-060.2678image
chr1:150731082-150734568:-LUADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.0890e-060.2081image
ENSG00000163131.9,CTSSLUADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.4576e-060.2112image
ENSG00000163131.9,CTSSMESOGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG4.1293e-020.2446image
chr1:150731082-150734568:-MESOGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.2128e-020.2436image
chr1:150731082-150734568:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.4200e-040.1984image
ENSG00000163131.9,CTSSOVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.8897e-030.1859image
ENSG00000163131.9,CTSSPAADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.5532e-06-0.3349image
chr1:150731082-150734568:-PAADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER8.5826e-06-0.3330image
chr1:150731082-150734568:-PCPGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER9.2419e-090.5381image
ENSG00000163131.9,CTSSPCPGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.8577e-090.5510image
ENSG00000163131.9,CTSSPRADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG3.7791e-100.3145image
chr1:150731082-150734568:-PRADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER3.6382e-100.3148image
ENSG00000163131.9,CTSSSARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.6180e-050.2616image
chr1:150731082-150734568:-SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.2453e-050.2779image
chr1:150731082-150734568:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5854e-050.2012image
ENSG00000163131.9,CTSSSKCMGSVA_HALLMARK_COAGULATIONEAG3.9737e-050.2000image
chr1:150753026-150754260:-STADGSVA_HALLMARK_ANGIOGENESISEER2.9526e-030.5086image
chr1:150731082-150734568:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.0620e-040.1797image
ENSG00000163131.9,CTSSSTADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3792e-040.1851image
chr1:150731082-150734568:-TGCTGSVA_HALLMARK_G2M_CHECKPOINTEER1.9198e-02-0.2076image
ENSG00000163131.9,CTSSTGCTGSVA_HALLMARK_G2M_CHECKPOINTEAG2.0525e-02-0.2054image
ENSG00000163131.9,CTSSTHCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.1564e-040.1747image
chr1:150731082-150734568:-THCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER8.7423e-050.1777image
ENSG00000163131.9,CTSSTHYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0167e-030.3444image
chr1:150731082-150734568:-THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0974e-030.3423image
ENSG00000163131.9,CTSSUCECGSVA_HALLMARK_KRAS_SIGNALING_UPEAG4.5283e-050.3550image
chr1:150731082-150734568:-UCECGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.1684e-050.3644image
ENSG00000163131.9,CTSSUCSGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.7625e-020.3479image
chr1:150731082-150734568:-UCSGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.7046e-020.3488image
chr1:150731082-150734568:-UVMGSVA_HALLMARK_MYOGENESISEER8.2278e-03-0.4121image
ENSG00000163131.9,CTSSUVMGSVA_HALLMARK_MYOGENESISEAG8.0406e-03-0.4132image


Top

7. Enriched editing regions and drugs for CTSS


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000163131.9,CTSSACCBIRB.0796EAG2.6840e-02-0.3041image
chr1:150731082-150734568:-ACCBIRB.0796EER2.6595e-02-0.3046image
ENSG00000163131.9,CTSSBLCADocetaxelEAG1.3937e-02-0.1350image
chr1:150731082-150734568:-BLCACMKEER8.8057e-03-0.1444image
ENSG00000163131.9,CTSSBRCADMOGEAG9.2910e-070.1525image
chr1:150731082-150734568:-BRCADMOGEER1.2795e-060.1506image
chr1:150731082-150734568:-CESCBMS.754807EER4.7870e-03-0.1751image
ENSG00000163131.9,CTSSCESCBMS.754807EAG4.0011e-03-0.1783image
ENSG00000163131.9,CTSSCHOLBIRB.0796EAG3.2502e-020.3788image
chr1:150731082-150734568:-CHOLBIRB.0796EER3.2684e-020.3785image
ENSG00000163131.9,CTSSCOADGefitinibEAG2.7841e-02-0.1324image
chr1:150731082-150734568:-COADGefitinibEER2.5809e-02-0.1342image
chr1:150731082-150734568:-DLBCJNK.9LEER8.6857e-030.3786image
ENSG00000163131.9,CTSSDLBCJNK.9LEAG7.6457e-030.3844image
chr1:150731082-150734568:-GBMGefitinibEER1.4639e-02-0.1892image
ENSG00000163131.9,CTSSGBMGefitinibEAG1.4508e-02-0.1894image
ENSG00000163131.9,CTSSHNSCDMOGEAG6.8972e-04-0.1627image
chr1:150731082-150734568:-HNSCDMOGEER8.5349e-04-0.1599image
chr1:150731082-150734568:-KICHMethotrexateEER1.6140e-03-0.4266image
ENSG00000163131.9,CTSSKICHMethotrexateEAG1.5811e-03-0.4273image
ENSG00000163131.9,CTSSKIRCAZD6482EAG1.2305e-120.3595image
chr1:150731082-150734568:-KIRCAZD6482EER1.7160e-120.3573image
chr1:150731082-150734568:-KIRPLenalidomideEER7.9498e-030.1682image
ENSG00000163131.9,CTSSKIRPLenalidomideEAG5.0430e-030.1776image
ENSG00000163131.9,CTSSLAMLBAY.61.3606EAG1.0902e-030.2659image
chr1:150731082-150734568:-LAMLBAY.61.3606EER5.2423e-040.2817image
chr1:150731082-150734568:-LGGErlotinibEER2.4399e-06-0.2263image
ENSG00000163131.9,CTSSLGGErlotinibEAG2.4844e-06-0.2261image
ENSG00000163131.9,CTSSLIHCBI.2536EAG7.9842e-03-0.1488image
chr1:150731082-150734568:-LIHCBMS.708163EER3.5314e-05-0.2308image
ENSG00000163131.9,CTSSLUADAP.24534EAG3.4603e-070.2232image
chr1:150731082-150734568:-LUADATRAEER3.4023e-070.2233image
chr1:150731082-150734568:-LUSCBicalutamideEER3.7351e-02-0.0966image
ENSG00000163131.9,CTSSLUSCBicalutamideEAG3.2984e-02-0.0989image
ENSG00000163131.9,CTSSMESOAS601245EAG1.3495e-020.2940image
chr1:150731082-150734568:-MESOAS601245EER1.4402e-020.2914image
ENSG00000163131.9,CTSSOVA.770041EAG7.0816e-030.1615image
chr1:150731082-150734568:-OVA.770041EER1.2579e-020.1503image
ENSG00000163131.9,CTSSPAADBortezomibEAG1.5493e-04-0.2862image
chr1:150731082-150734568:-PAADBortezomibEER1.2350e-04-0.2902image
chr1:150731082-150734568:-PCPGAP.24534EER1.9729e-03-0.3073image
ENSG00000163131.9,CTSSPCPGAP.24534EAG5.5252e-04-0.3394image
ENSG00000163131.9,CTSSPRADJNK.Inhibitor.VIIIEAG4.4898e-05-0.2080image
chr1:150731082-150734568:-PRADJNK.Inhibitor.VIIIEER4.4288e-05-0.2082image
ENSG00000163131.9,CTSSREADGDC.0449EAG1.9773e-040.3748image
chr1:150731082-150734568:-READGDC.0449EER2.4780e-040.3694image
ENSG00000163131.9,CTSSSARCCI.1040EAG1.1171e-04-0.2536image
chr1:150731082-150734568:-SARCCI.1040EER1.6419e-05-0.2823image
chr1:150731082-150734568:-SKCMDoxorubicinEER1.3350e-050.2117image
ENSG00000163131.9,CTSSSKCMDoxorubicinEAG2.0555e-050.2072image
chr1:150753026-150754260:-STADAZ628EER3.2738e-02-0.3784image
chr1:150731082-150734568:-STADA.770041EER1.3891e-02-0.1278image
ENSG00000163131.9,CTSSSTADA.770041EAG1.0910e-02-0.1322image
chr1:150740453-150742182:-STADJNK.Inhibitor.VIIIEER3.3618e-020.4444image
ENSG00000163131.9,CTSSTGCTAZ628EAG4.4911e-02-0.1783image
chr1:150731082-150734568:-TGCTAZ628EER4.1034e-02-0.1816image
ENSG00000163131.9,CTSSTHCAGW.441756EAG2.2746e-04-0.1672image
chr1:150731082-150734568:-THCAGW.441756EER2.8499e-04-0.1646image
chr1:150731082-150734568:-THYMImatinibEER1.2162e-03-0.3394image
ENSG00000163131.9,CTSSTHYMImatinibEAG1.1411e-03-0.3412image
ENSG00000163131.9,CTSSUCECIPA.3EAG9.4191e-030.2305image
chr1:150731082-150734568:-UCECMethotrexateEER4.4915e-03-0.2546image
ENSG00000163131.9,CTSSUCSAICAREAG1.2790e-02-0.4109image
chr1:150731082-150734568:-UCSAICAREER1.2799e-02-0.4109image
ENSG00000163131.9,CTSSUVMEtoposideEAG7.6421e-03-0.4157image
chr1:150731082-150734568:-UVMEtoposideEER7.6185e-03-0.4158image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr1:150731082-150734568:-ENST00000368985.6P25774DB12010FostamatinibSmallMoleculeDrug
chr1:150731082-150734568:-ENST00000448301.5P25774DB12010FostamatinibSmallMoleculeDrug
chr1:150740453-150742182:-ENST00000368985.6P25774DB12010FostamatinibSmallMoleculeDrug
chr1:150740453-150742182:-ENST00000448301.5P25774DB12010FostamatinibSmallMoleculeDrug